More providers are fielding patient questions about compounded therapies as demand climbs in weight management and hormone care. That interest has arrived alongside tighter regulatory scrutiny, most visible around compounded glucagon-like peptide-1 (GLP-1) products and the online prescribing models that offer them.

That growth makes regulatory distinctions increasingly important.

The 503A Model, Defined

“Traditional compounding” usually means the 503A model: a state-licensed pharmacist prepares a customized medication for an identified patient under a valid prescription. One patient, one prescription.

What Section 503A Exempts

The Food, Drug, and Cosmetic Act Section 503A sets the federal conditions under which traditional pharmacy compounding may qualify for exemptions. If it meets those conditions, the compounded drug is exempt from federal requirements for FDA approval before marketing, adequate directions-for-use labeling, and certain current good manufacturing practice (cGMP) standards.

Who Oversees a 503A Pharmacy?

State boards of pharmacy oversee day-to-day operations. A facility needs a resident pharmacy license in its home state plus non-resident licenses for every state it ships into. On the operations side, USP <795> and USP <797> set the standards for nonsterile and sterile compounding, while USP <800> governs the safe handling of hazardous drugs.

Ask for those licenses in writing before the first prescription leaves your office, because a resident license on its own tells you nothing about whether the pharmacy can legally ship to your patient. MediVera, which fills patient-specific prescriptions as a 503A compounding pharmacy, answers to the board in each state it serves, and every one of those licenses is something your staff can confirm without taking the pharmacy’s word for it.

How 503A Differs From Other Pharmacy Models

A pharmacy’s regulatory class determines its production scale and its legal authority to distribute. Here is how the three models line up.

Feature	503A Compounding Pharmacy	503B Outsourcing Facility	Traditional Retail Pharmacy
Primary Function	Prepares customized formulations for identified individual patients	Compounds large batches for office stock and healthcare facilities	Dispenses commercially manufactured, FDA-approved medications
Main Oversight	State Boards of Pharmacy (primary); FDA under Section 503A conditions	FDA (primary registration & cGMP inspections); State Boards	State Boards of Pharmacy
Prescription Requirement	Valid patient-specific prescription required prior to dispensing	No patient-specific prescription required; office stock permitted	Valid patient-specific prescription required
Quality Standards	USP standards (<795>, <797>, <800>)	Current Good Manufacturing Practice (cGMP) standards	Commercial cGMP standards; USP dispensing rules
FDA Approval Status	Unapproved (exempt from premarket approval)	Unapproved (exempt from premarket approval)	Fully FDA-approved
Best Use Case	Unique individual needs (allergies, custom strengths, liquid forms)	Provider office inventory, hospital supply, volume-driven shortages	Standard commercial prescription needs

Office Stock vs. Patient-Specific Dispensing

A critical operational distinction between models is the prohibition of “office stock” at the 503A level. Section 503A compounding pharmacies are legally barred from providing bulk, unassigned medications for clinical office inventory. They may only dispense a preparation after receiving a valid prescription tied to a specific patient. If your practice needs bulk inventory to keep on hand for in-office administration, source those orders through a 503B outsourcing facility.

Why the Distinction Matters More Now

Your pharmacy partner’s classification carries legal and operational weight it didn’t a few years ago. The FDA is reviewing telehealth and online prescribing models that make false or misleading claims about compounded GLP-1 products and dispense compounded medications with little meaningful clinician involvement. Ongoing FDA meetings on whether specific unapproved substances belong on the 503A bulks list have added to the uncertainty about what can legally be compounded at all.

Verifying a Pharmacy Before You Prescribe

“503A” is a regulatory classification, not a quality rating. Check licensure and compounding scope yourself, along with the quality systems behind both, before you transmit a patient’s prescription.

What to Check Before You Send a Prescription

Work through this once per pharmacy and keep the answers on file.

• Confirm an active state pharmacy license in the dispensing state.
• Verify non-resident licenses if the pharmacy ships across state lines.
• Ask which USP chapters apply to its scope, and whether that scope includes sterile or hazardous preparations.
• Confirm that it requires a valid patient-specific prescription before dispensing.
• Review inspection and disciplinary history through the state board, then check FDA records for warning letters.
• Ask where active ingredients are sourced and how beyond-use dates get assigned.
• Ask what quality assurance testing supports each preparation, and whether formulas and testing standards are documented.
• Check for voluntary accreditation, such as Pharmacy Compounding Accreditation Board (PCAB) accreditation.
• Clarify turnaround time and who counsels the patient.
• Ask whether the pharmacy can absorb your prescription volume without loosening quality controls, and how adverse events get reported back to you.

Where to Look

Start with the state board of pharmacy license lookup tool in the patient’s home state. National Association of Boards of Pharmacy resources will confirm active, unencumbered licenses. For federal history, search the FDA’s inspection database for facility warning letters and documented compliance issues.

Build these checks into the pharmacy onboarding workflow.

Why Compounded Is Not the Same as FDA-Approved

Plenty of patients assume anything dispensed by a licensed pharmacy carries FDA approval. Compounded medications do not go through the agency’s premarket review for safety and effectiveness, and no regulator signs off on manufacturing consistency before the preparation reaches the patient.

What to Tell Patients

The gap between what patients believe and what is true is wide. One 2026 survey found that only 17% of consumers correctly knew that compounded GLP-1s were not FDA-approved. Many assume compounded products clear the same clinical trials and quality reviews as commercially manufactured ones. Say the difference out loud, in plain language, and note in the chart that you did.

High-Demand Categories Raise the Stakes

Weight management and hormone therapy rely on compounding when commercial products run short or when dosing must be specialized. The FDA has warned facilities that allegedly made false or misleading claims about the equivalence and safety of their compounded products.

Under Section 503A, active pharmaceutical ingredients (APIs) used in compounding must meet specific statutory standards. To be legally compounded, a bulk drug substance must fulfill at least one of three criteria:

• Comply with an official United States Pharmacopeia (USP) or National Formulary (NF) monograph,
• Be a component of an FDA-approved drug, or
• Appear on the FDA’s 503A Bulk Drug Substances List.

While inclusion on the 503A bulks list allows an unapproved substance (such as certain peptides) to be legally used in compounding, that listing alone does not constitute an FDA endorsement of safety or efficacy.

The Role of the FDA Drug Shortages List

Federal law strictly limits 503A pharmacies from compounding medications that are “essentially copies” of FDA-approved, commercially available products. The primary exception occurs when a drug appears on the official FDA Drug Shortages database. While a commercial brand (such as a GLP-1) is actively listed as in shortage, 503A pharmacies may legally compound patient-specific alternatives to fill supply gaps. Once the FDA deems a shortage resolved and removes the drug from the list, 503A facilities must cease routine compounding of that product unless an individual patient requires a documented clinical variation, such as an alternative strength or allergen-free formulation.

When Compounding Still Makes Sense

Compounded medications have legitimate clinical uses. A patient allergic to a commercial excipient, a patient who needs a dosage form nobody markets, or a patient who needs a strength no manufacturer makes: each is a defensible reason to prescribe a compounded alternative. What matters is that the prescriber documents the specific patient need before the prescription goes out.

The Practical Standard

The practical standard is one habit: treat the pharmacy as part of the clinical decision, not a downstream vendor. The classification tells you which rules apply; the license lookup tells you whether the pharmacy is following them.

Documentation is where this turns operational. Electronic health records and patient engagement tools give your team a place to record why a compounded preparation was chosen and how the follow-up conversation went, the same operational rigor you would bring to revenue cycle management or any other administrative process. Your pharmacy partners deserve the same scrutiny.

Disclaimer:
This article is intended for general informational and educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Please consult a qualified healthcare provider for any health-related concerns or before making decisions about medications or treatment plans. Never disregard or delay seeking professional medical advice based on information found here. In case of a medical emergency, contact your local emergency services immediately.